Avalon Global Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Avalon Global Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-23,060	Closed	-$3.3M	–	40
2019 Q1	$3.3M	Sell	23,060 -5,000	-18%	-$652K	1.76%	28
2018 Q4	$3.48M	Buy	28,060 +930	+3%	+$138K	2.11%	23
2018 Q3	$4.56M	Hold	27,130	–	–	1.57%	30
2018 Q2	$4.67M	Hold	27,130	–	–	1.7%	30
2018 Q1	$4.1M	Buy	27,130 +5,000	+23%	+$733K	1.41%	33
2017 Q4	$2.98M	Hold	22,130	–	–	1.48%	33
2017 Q3	$3.24M	Hold	22,130	–	–	1.23%	31
2017 Q2	$3.44M	Sell	22,130 -5,000	-18%	-$765K	1.92%	27
2017 Q1	$3.94M	Buy	27,130 +12,500	+85%	+$1.63M	2.05%	25
2016 Q4	$1.59M	Sell	14,630 -12,870	-47%	-$1.43M	1.31%	30
2016 Q3	$3.34M	Buy	27,500 +5,000	+22%	+$674K	2%	26
2016 Q2	$3.18M	Sell	22,500 -2,500	-10%	-$369K	1.84%	22
2016 Q1	$3.26M	Buy	+25,000	New	+$3.11M	2.47%	18

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Avalon Global Asset Management's JAZZ Position: Q2 2019 in Review

Avalon Global Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2019, closing a stake of 23,060 shares — an estimated $3.3M sold.

Avalon Global Asset Management first reported a position in JAZZ in Q1 2016 and held it in 13 quarters. The position peaked at $4.67M in Q2 2018. 416 funds tracked by Wall St. Rank hold JAZZ as of Q2 2019.

Avalon Global Asset Management reported no remaining Jazz Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Avalon Global Asset Management sold 23,060 Jazz Pharmaceuticals shares in Q2 2019, an estimated $3.3M.
Avalon Global Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2016 and held it in 13 quarters.
Avalon Global Asset Management's Jazz Pharmaceuticals position peaked at $4.67M in Q2 2018.
416 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2019.

Based on Avalon Global Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.